Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
This PHASE3 trial investigates Essential Hypertension and is currently completed. Shanghai Pharmaceuticals Holding Co., Ltd leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Dec 2023 — Jun 2024 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Jun 2022 — Mar 2023 [monthly]
Recruiting PHASE3
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Pharmaceuticals Holding Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Cangzhou, China , Changsha, China , Chengdu, China , Chifeng, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Hohhot, China and 18 more locations